A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data
暂无分享,去创建一个
Chuang Lu | Suresh K Balani | Gerald T Miwa | Liang-Shang Gan | Chuang Lu | L. Gan | G. Miwa | Shimoga R Prakash | S. Prakash | S. Balani
[1] F. Gonzalez,et al. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. , 1999, Trends in pharmacological sciences.
[2] R. Obach,et al. Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[3] Y. Sugiyama,et al. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P 4503A4 , 1999, AAPS PharmSci.
[4] A. Y. Lu,et al. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[5] K. Brouwer,et al. AGI July 40/1 , 1999 .
[6] Chuang Lu,et al. RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB , 2005, Drug Metabolism and Disposition.
[7] Bruno Stieger,et al. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[8] Aleksandra Galetin,et al. PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION , 2006, Drug Metabolism and Disposition.
[9] Kiyomi Ito,et al. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.
[10] R. Miller,et al. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[11] Robert J Riley,et al. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. , 2003, British journal of clinical pharmacology.
[12] M. Shameem,et al. A short-term (accelerated release) approach to evaluate peptide release from PLGA depot formulations , 1999, AAPS PharmSci.
[13] C. Xia,et al. EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS , 2005, Drug Metabolism and Disposition.
[14] Shiew-Mei Huang,et al. Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus , 2001, Pharmaceutical Research.
[15] E. Burton,et al. Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[16] A. Y. Lu,et al. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[17] Y. Sugiyama,et al. Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. , 2003, Drug metabolism and pharmacokinetics.
[18] M. Leider. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .
[19] O Pelkonen,et al. Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[20] D. Greenblatt,et al. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.
[21] Jenny Y Chien,et al. STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE , 2006, Drug Metabolism and Disposition.
[22] C. Crespi. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .
[23] S. D. Turner,et al. Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[24] K. Korzekwa,et al. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. , 2000, European journal of pharmacology.
[25] Kiyomi Ito,et al. IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM , 2005, Drug Metabolism and Disposition.
[26] J. Houston,et al. The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[27] J B Houston,et al. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.
[28] Leslie Z. Benet,et al. Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat , 1998, Pharmacology.
[29] K. Bachmann,et al. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. , 2006, Current drug metabolism.
[30] A. Li,et al. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. , 2001, Chemico-biological interactions.
[31] M. Schäfer-Korting,et al. Ketoconazole concentrations in human skin blister fluid and plasma. , 1984, International journal of clinical pharmacology, therapy, and toxicology.
[32] Jing-Tao Wu,et al. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. , 2005, Current topics in medicinal chemistry.
[33] Y. Berger,et al. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[34] K. Carroll,et al. Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[35] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[36] M. Ratain,et al. Effects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes , 2005, Clinical Cancer Research.
[37] Amy Roe,et al. The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective , 2003, Journal of clinical pharmacology.
[38] Masato Chiba,et al. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[39] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[40] A. Li,et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. , 1999, Chemico-biological interactions.
[41] T. Ebner,et al. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. , 1999, The Journal of pharmacology and experimental therapeutics.
[42] C. Rochlitz,et al. Cytotoxicity of ketoconazole in malignant cell lines , 2004, Cancer Chemotherapy and Pharmacology.
[43] T Lavé,et al. Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. , 2004, Current drug metabolism.
[44] Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[45] M. Snow,et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. , 1996, Biochemical pharmacology.